A specific immune signature for predicting the prognosis of glioma patients with IDH1-mutation and guiding immune checkpoint blockade therapy

A specific immune signature for predicting the prognosis of glioma patients with IDH1-mutation and guiding immune checkpoint blockade therapy

Isocitrate dehydrogenase (IDH1) is frequently mutated in glioma tissues, and this mutation mediates specific tumor-promoting mechanisms in glioma cells. We aimed to identify specific immune biomarkers for IDH1-mutation (IDH1mt) glioma. The Cancer Genome Atlas (TCGA) and Chinese Glioma Genome Atlas (...

Full description

Bibliographic Details
Main Authors: Zhirui Zeng, Chujiao Hu, Wanyuan Ruan, Jinjuan Zhang, Shan Lei, Yushi Yang, Pailan Peng, Feng Pan, Tengxiang Chen
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-09-01
Series:Frontiers in Immunology
Subjects:
immune
signature
glioma
IDH1 mutation
immune checkpoint blockade therapy
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.1001381/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.1001381/full

Similar Items